Processing

Please wait...

Settings

Settings

1. WO1996005832 - METHODS OF INHIBITING PRIMARY ENDOMETRIAL HYPERPLASIA

Publication Number WO/1996/005832
Publication Date 29.02.1996
International Application No. PCT/US1995/010619
International Filing Date 21.08.1995
Chapter 2 Demand Filed 31.01.1996
IPC
A61K 31/381 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
381having five-membered rings
A61K 31/4025 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4025not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4535 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4535containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
CPC
A61K 31/381
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
381having five-membered rings
A61K 31/4025
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4025not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4535
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4535containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61P 13/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
02of urine or of the urinary tract, e.g. urine acidifiers
A61P 15/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
Applicants
  • ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, IN 46285, US
Inventors
  • FUCHS-YOUNG, Robin, Sharon, Lee; US
Agents
  • LAMMERT, Steven, R.; Barnes & Thornburg 1313 Merchants Bank Building 11 South Meridian Street Indianapolis, IN 46204, US
Priority Data
08/294,12122.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF INHIBITING PRIMARY ENDOMETRIAL HYPERPLASIA
(FR) PROCEDES ENRAYANT L'HYPERPLASIE ENDOMETRIALE PRIMAIRE
Abstract
(EN)
A method of inhibiting primary endometrial hyperplasia comprising administering to a human in need thereof an effective amount of a compound having formula (I) wherein R1 and R3 are independently hydrogen, -CH3, (a) or (b), wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt or solvate thereof.
(FR)
Le procédé enrayant l'hyperplasie endométriale primaire de la présente invention consiste à administrer à un être humain le nécessitant une quantité suffisante d'un composant représenté par la formule générale (I) ou de l'un de ses sels ou solvates pharmaceutiquement acceptables. Dans cette formule générale R1 et R3 sont indépendamment hydrogène, -CH3, -C(=O)-C1-C6 alkyle, ou -C(=O)-Ar, où Ar est un phényle éventuellement substitué. R2 appartient au groupe formé par pyrrolidine, hexaméthylèneimino et pipéridino; ou un sel ou solvate pharmaceutiquement acceptable du composé.
Also published as
CZPV1997-522
FI970716
NO19970787
NZ292345
Other related publications
Latest bibliographic data on file with the International Bureau